Abstract
The field of aging and dementia research is advancing rapidly toward the stage of earlier identification of clinical symptoms. Ultimately, clinicians would like to be able to identify individuals who are asymptomatic but at risk for developing dementia. In the interim, the construct of mild cognitive impairment (MCI) has come to represent an intermediate clinical state between the cognitive changes of aging and the very earliest features of Alzheimers disease. A great deal of research has been generated in the past several years on MCI, and epidemiologic studies are characterizing its frequency in the general population. There are predictors of a more rapid progression from MCI to Alzheimers disease, and these studies are suggesting techniques for altering future clinical trials. The neuropathology of MCI is intermediate between the neuropathologic changes of aging and fully developed Alzheimers disease. The breadth of research in MCI is expanding and will be reviewed.
Keywords: Mild cognitive impairment, Alzheimer's disease, aging
Current Alzheimer Research
Title: Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Volume: 6 Issue: 4
Author(s): Ronald C. Petersen
Affiliation:
Keywords: Mild cognitive impairment, Alzheimer's disease, aging
Abstract: The field of aging and dementia research is advancing rapidly toward the stage of earlier identification of clinical symptoms. Ultimately, clinicians would like to be able to identify individuals who are asymptomatic but at risk for developing dementia. In the interim, the construct of mild cognitive impairment (MCI) has come to represent an intermediate clinical state between the cognitive changes of aging and the very earliest features of Alzheimers disease. A great deal of research has been generated in the past several years on MCI, and epidemiologic studies are characterizing its frequency in the general population. There are predictors of a more rapid progression from MCI to Alzheimers disease, and these studies are suggesting techniques for altering future clinical trials. The neuropathology of MCI is intermediate between the neuropathologic changes of aging and fully developed Alzheimers disease. The breadth of research in MCI is expanding and will be reviewed.
Export Options
About this article
Cite this article as:
Petersen C. Ronald, Early Diagnosis of Alzheimers Disease: Is MCI Too Late?, Current Alzheimer Research 2009; 6 (4) . https://dx.doi.org/10.2174/156720509788929237
DOI https://dx.doi.org/10.2174/156720509788929237 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry Conference Report: 7th Clinical Trials on Alzheimer’s Disease Annual Conference, Philadelphia, PA, USA Nov 20-22, 2014
CNS & Neurological Disorders - Drug Targets Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Strategies and Novel Drug Approaches for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Comparing Age Effects in Normally and Extremely Highly Educated and Intellectually Engaged 65 - 80 Year-olds: Potential Protection from Deficit Through Educational and Intellectual Activities Across the Lifespan
Current Aging Science Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity
Current Alzheimer Research Translational Challenge Models in Support of Efficacy Studies: Effect of Cerebral Hypoxia on Cognitive Performances in Rodents
CNS & Neurological Disorders - Drug Targets CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design Role of Protein Phosphatase 2A in Alzheimers Disease
Current Alzheimer Research Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals Therapeutic Perspectives of Drugs Targeting Toll-Like Receptors Based on Immune Physiopathology Theory of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets New Developments in Oral Vaccines and Mucosal Adjuvants
Recent Patents on Inflammation & Allergy Drug Discovery Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes
Current Neurovascular Research Neuroinflammatory Markers in Spontaneously Hypertensive Rat Brain: An Immunohistochemical Study
CNS & Neurological Disorders - Drug Targets EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research